m
Recent Posts
Connect with:
Friday / May 27.
HomeminewsAFT to Distribute NovaTears

AFT to Distribute NovaTears

AFT Pharmaceuticals (AFT) has completed a licensing agreement with Novaliq, a German specialty pharmaceutical company, to distribute NovaTears in Australia and New Zealand. NovaTears is an ophthalmic product for the treatment of evaporative dry eye diseases (DEDs) developed by Novaliq and sold across Europe under the brand name EvoTears.

Dr. Hartley Atkinson, CEO of AFT said NovaTears would be welcomed by doctors and patients alike. “It’s a first-in-class, water-free and preservative-free treatment based on Novaliq’s proprietary EyeSol technology platform. NovaTears supports the lipid layer of the tear film by its ability to quickly spread and be absorbed into the eye. We believe that this feature – combined with its small droplet size – will provide superior benefits to patients with evaporative dry eye disease.”

Christian Roesky, PhD, CEO of Novaliq said, “NovaTears provides a highly differentiated and clinically validated treatment option that significantly improves the signs and symptoms of evaporative DED and Meibomian gland dysfunction, highly underserved diseases. We are confident that dry eye patients in Australasia will greatly benefit from the use of NovaTears and
our partnership with AFT.”

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.